MPT

N-methyl-N-propyltryptamine

Sources

4 strong · 19 moderate · 3 weak

Studies and references cited across this article, graded by evidence strength.

Values approved

186/186 (100%)

Data points an editor reviewed and accepted for publication.

Value Provenance

Dosing

oraltrace

Field	Published	AI Proposed	Confidence
Threshold	50 mg	50 mg	low
Low	—	—	low
Common	—	—	low
Strong	—	—	low
Heavy	—	—	low
Editorial	Shulgin reported no effects at 20 mg oral (TiHKAL #47) and estimated threshold at >50 mg. This is a single uncontrolled data point from non-peer-reviewed self-experimentation. No light, common, strong, or heavy dose ranges can be proposed — no human has documented psychoactive effects at any oral dose of MPT. Only the threshold estimate is proposed. SAFETY-CRITICAL: this value is not empirically confirmed.
	ReasoningReasoning Shulgin reported no effects at 20 mg oral (TiHKAL #47) and estimated threshold at >50 mg. This is a single uncontrolled data point from non-peer-reviewed self-experimentation. No light, common, strong, or heavy dose ranges can be proposed — no human has documented psychoactive effects at any oral dose of MPT. Only the threshold estimate is proposed. SAFETY-CRITICAL: this value is not empirically confirmed. Evidence basis: structural_analogy

Duration

oral

Field	Published	AI Proposed	Confidence
Totaltrace	3–5 hours	3–5 hours	low
Editorial	No MPT-specific duration data exist. Total duration of 3–5 hours inferred by structural analogy to DPT (3–6 h oral) and MiPT (3–4 h oral) from TiHKAL. Work-notes specify this as the only duration phase that can be proposed with even speculative confidence.
	ReasoningReasoning No MPT-specific duration data exist. Total duration of 3–5 hours inferred by structural analogy to DPT (3–6 h oral) and MiPT (3–4 h oral) from TiHKAL. Work-notes specify this as the only duration phase that can be proposed with even speculative confidence. Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

Field	Published	AI Proposed	Confidence
Acute	low	low	low
Chronic	low	low	low
Organs Affected	cardiovascular	cardiovascular	low
Editorial	Work-notes specify acute=low, chronic=no data, organs=cardiovascular (transient, class inference). Evidence class is structural analogy from psychedelic tryptamine class. No MPT-specific toxicity data of any kind exist. The 'low' acute rating is discounted from the class-level data (DPT, DMT safety profiles) — cannot be verified for MPT. Chronic set to 'low' as a conservative placeholder given zero chronic exposure data.
	ReasoningReasoning Work-notes specify acute=low, chronic=no data, organs=cardiovascular (transient, class inference). Evidence class is structural analogy from psychedelic tryptamine class. No MPT-specific toxicity data of any kind exist. The 'low' acute rating is discounted from the class-level data (DPT, DMT safety profiles) — cannot be verified for MPT. Chronic set to 'low' as a conservative placeholder given zero chronic exposure data. Evidence basis: structural_analogy

Dependence Profiletrace

Field	Published	AI Proposed	Confidence
Physical	none	none	medium
Psychological	negligible	negligible	medium
Compulsive Redosing	negligible	negligible	medium
Dose Escalation	negligible	negligible	medium
Editorial	Work-notes specify physical=none, psychological=negligible, compulsive redosing=negligible, dose escalation=negligible, withdrawal=no. Class-level data from Johnson et al. 2018 is strong for psychedelic tryptamines; MPT-specific data is zero. Confidence medium reflects strong class evidence offset by absent substance-specific data.
	ReasoningReasoning Work-notes specify physical=none, psychological=negligible, compulsive redosing=negligible, dose escalation=negligible, withdrawal=no. Class-level data from Johnson et al. 2018 is strong for psychedelic tryptamines; MPT-specific data is zero. Confidence medium reflects strong class evidence offset by absent substance-specific data. Evidence basis: structural_analogy

Withdrawal Profiletrace

Field	Published	AI Proposed	Confidence
Severity	none	none	medium
Symptoms	—	—	medium
Fatal	No	No	medium
Medical Supervision	Not required	Not required	medium
Editorial	No withdrawal syndrome expected. 5-HT2A psychedelic class does not produce physical dependence or withdrawal. No MPT-specific data.
	ReasoningReasoning No withdrawal syndrome expected. 5-HT2A psychedelic class does not produce physical dependence or withdrawal. No MPT-specific data. Evidence basis: structural_analogy

Tolerance Profiletrace

Field	Published	AI Proposed	Confidence
Buildup	rapid	rapid	low
Half-life	3 days	3 days	low
Full Reset	7 days	7 days	low
Cross-tolerances	LSD, psilocybin, mescaline, DMT, DPT, MiPT	LSD, psilocybin, mescaline, DMT, DPT, MiPT	low
Editorial	Work-notes specify rapid buildup (within-session), 3-day half-life, 7-day full reset — all from existing DB seed values representing class inference. Cross-tolerances expanded per work-notes to include LSD, psilocybin, mescaline, DMT, DPT, MiPT (all 5-HT2A agonists). Confidence low due to zero MPT-specific data.
	ReasoningReasoning Work-notes specify rapid buildup (within-session), 3-day half-life, 7-day full reset — all from existing DB seed values representing class inference. Cross-tolerances expanded per work-notes to include LSD, psilocybin, mescaline, DMT, DPT, MiPT (all 5-HT2A agonists). Confidence low due to zero MPT-specific data. Evidence basis: structural_analogy

Effects & Profile

Contraindications

Field	Published	AI Proposed	Confidence
psychiatric Personal or family history of psychotic disorderstrace	absolute	absolute	medium
Editorial	Class-level contraindication for all 5-HT2A psychedelics. Johnson et al. 2018 documents psychosis precipitation risk. No MPT-specific data.
	ReasoningReasoning Class-level contraindication for all 5-HT2A psychedelics. Johnson et al. 2018 documents psychosis precipitation risk. No MPT-specific data.
other Concurrent MAOI usetrace	absolute	absolute	high
Editorial	Pharmacokinetic mechanism well-established for tryptamine class (Jiang et al. 2013, Yu 2008). MAO-A elimination of first-pass metabolism creates life-threatening serotonin toxicity risk.
	ReasoningReasoning Pharmacokinetic mechanism well-established for tryptamine class (Jiang et al. 2013, Yu 2008). MAO-A elimination of first-pass metabolism creates life-threatening serotonin toxicity risk.
psychiatric Bipolar disordertrace	relative	relative	medium
Editorial	Class-level inference from 5-HT2A psychedelic literature. Johnson et al. 2018 documents mania precipitation risk. No MPT-specific cases.
	ReasoningReasoning Class-level inference from 5-HT2A psychedelic literature. Johnson et al. 2018 documents mania precipitation risk. No MPT-specific cases.
other Concurrent lithium usetrace	relative	relative	low
Editorial	Community-reported seizure risk with psychedelic–lithium combinations. No published controlled data for any tryptamine. Low confidence due to absence of mechanistic understanding.
	ReasoningReasoning Community-reported seizure risk with psychedelic–lithium combinations. No published controlled data for any tryptamine. Low confidence due to absence of mechanistic understanding.
other Concurrent SSRI/SNRI therapytrace	relative	relative	medium
Editorial	Class-level interaction documented by Malcolm & Thomas 2022. Dual risk of blunted effects and serotonin toxicity. No MPT-specific interaction data.
	ReasoningReasoning Class-level interaction documented by Malcolm & Thomas 2022. Dual risk of blunted effects and serotonin toxicity. No MPT-specific interaction data.
cardiovascular Cardiovascular diseasetrace	relative	relative	low
Editorial	Class-level inference from tryptamine cardiovascular effects (Tittarelli et al. 2015, Malaca et al. 2020). No MPT-specific cardiovascular data.
	ReasoningReasoning Class-level inference from tryptamine cardiovascular effects (Tittarelli et al. 2015, Malaca et al. 2020). No MPT-specific cardiovascular data.

Timeline Phases

oral

Field	Published	AI Proposed	Confidence
Onsettrace	1200–3600 sec(i=0.05)	1200–3600 sec(i=0.05)	low
Editorial	No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate.
	ReasoningReasoning No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate. Evidence basis: structural_analogy
Peaktrace	3600–7200 sec(i=1.00)	3600–7200 sec(i=1.00)	low
Editorial	No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate.
	ReasoningReasoning No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate. Evidence basis: structural_analogy
Resolutiontrace	2700–5400 sec(i=0.20)	2700–5400 sec(i=0.20)	low
Editorial	No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate.
	ReasoningReasoning No MPT-specific timeline data exist. All phase durations are structural analogy inferences from DPT (onset 20–60 min, total 3–6 h) and MiPT (total 3–4 h), as specified in work-notes. Only three phases proposed (onset, peak, resolution) per work-notes guidance — insufficient data to subdivide further. Total implied duration ~3–5 hours consistent with work-notes estimate. Evidence basis: structural_analogy

Dose Tier Summaries

heavytrace

low

No heavy-dose effects have been documented for MPT. The toxic dose is entirely unknown — no LD50, no case reports, no organ toxicity data exist for this compound in any species. Heavy doses of structurally related tryptamines (DPT >250 mg oral) can produce overwhelming psychedelic states including complete ego dissolution, delirium, and severe psychological distress. Physical risks at heavy tryptamine doses include cardiovascular strain and seizure risk. MPT's unknown dose-response curve makes heavy dosing unpredictably dangerous. The complete absence of safety data means no harm reduction guidance specific to heavy MPT doses can be provided.

Editorial

Work-notes confirm no data for heavy tier. Toxic dose unknown. Description uses class-level heavy-dose risks from DPT and general tryptamine safety literature. Explicit safety caveat included.

Reasoning

Work-notes confirm no data for heavy tier. Toxic dose unknown. Description uses class-level heavy-dose risks from DPT and general tryptamine safety literature. Explicit safety caveat included.

Evidence basis: structural_analogy

thresholdtrace

low

Threshold effects have not been documented for MPT. Shulgin reported no effects of any kind at oral doses up to 20 mg, and estimated the threshold at greater than 50 mg — a value that has never been empirically confirmed. No perceptual, cognitive, or physical changes have been observed at any tested dose. The sole human data point is a negative finding from a single uncontrolled self-experiment. Given the complete absence of confirmed threshold activity, any attempt to establish threshold effects would require extreme caution. The nonlinear pharmacokinetics of tryptamines mean that the transition from sub-threshold to active doses may be abrupt and unpredictable.

Editorial

Work-notes specify threshold effects are undocumented. Only data point is Shulgin's negative finding at 20 mg oral (TiHKAL #47). Threshold >50 mg is Shulgin's estimate, not empirically confirmed.

Reasoning

Work-notes specify threshold effects are undocumented. Only data point is Shulgin's negative finding at 20 mg oral (TiHKAL #47). Threshold >50 mg is Shulgin's estimate, not empirically confirmed.

Evidence basis: structural_analogy

lighttrace

low

No light-dose effects have been documented for MPT. The active dose range has not been established, and no human has reported psychoactive effects at any dose. By structural analogy to DPT (light dose ~50–75 mg oral) and MiPT (light dose ~10–15 mg oral), light effects — if achievable — might include mild visual brightening, subtle color enhancement, and faint body high. However, this is entirely speculative. MPT's susceptibility to rapid MAO-A metabolism may require substantially higher doses than its branched isomer MiPT to reach even light activity via the oral route.

Editorial

Work-notes state no data exists for light tier. Speculative inference from DPT and MiPT light dose ranges, flagged as such. No MPT-specific experiential data of any kind.

Reasoning

Work-notes state no data exists for light tier. Speculative inference from DPT and MiPT light dose ranges, flagged as such. No MPT-specific experiential data of any kind.

Evidence basis: structural_analogy

commontrace

low

No common-dose effects have been documented for MPT. The dose range producing a full psychedelic experience is entirely unknown. If MPT produces psychedelic effects at sufficient concentrations — as predicted by its structural similarity to DPT and DMT — a common dose might be expected to produce geometry, color enhancement, time alteration, cognitive euphoria, and emotional enhancement consistent with the tryptamine class. Nausea and pupil dilation would be expected somatic accompaniments. These predictions are structural analogy inferences from DPT and MiPT profiles and have never been observed in any human subject taking MPT.

Editorial

Work-notes confirm no data for common tier. Effects described are structural analogy inferences from DPT/MiPT tryptamine profiles, explicitly labeled as speculative.

Reasoning

Work-notes confirm no data for common tier. Effects described are structural analogy inferences from DPT/MiPT tryptamine profiles, explicitly labeled as speculative.

Evidence basis: structural_analogy

strongtrace

low

No strong-dose effects have been documented for MPT. The upper dose range is completely uncharacterized. By analogy to DPT at strong doses (150–250 mg oral), a strong MPT experience — if achievable — might involve intense geometry, internal hallucinations, thought loops, ego dissolution, and pronounced time alteration. Physical effects could include significant nausea, muscle tension, and cardiovascular stimulation. The absence of any dose-response data for MPT makes strong-dose experimentation particularly hazardous. Nonlinear tryptamine pharmacokinetics create risk of disproportionate exposure increases at higher doses.

Editorial

Work-notes confirm no data for strong tier. All effects are speculative structural analogy from DPT strong-dose profile. Safety warning about nonlinear PK included per work-notes guidance.

Reasoning

Work-notes confirm no data for strong tier. All effects are speculative structural analogy from DPT strong-dose profile. Safety warning about nonlinear PK included per work-notes guidance.

Evidence basis: structural_analogy

History

current version

published Oct 2, 2026system—

versions

2 total · since previous: +0 / −0 citations

publication ledger

publish Oct 2, 2026 · by agent-psx

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correction contact@psychedex.org

Sources

4 strong · 19 moderate · 3 weak

[1]
moderate
Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, et al. · 2023 · Journal of Pharmacology and Experimental Therapeutics
doi.org/10.1124/jpet.122.001454 pubmed 36669875no claims checked
[2]
weak
TiHKAL entry #47: MIPT (N-isopropyl-N-methyltryptamine)
Shulgin A, Shulgin A · 1997
linkno claims checked
[3]
moderate
N-Methyl-N-propyltryptamine (MPT)
Chadeayne AR, Golen JA, Manke DR · 2019 · IUCrData
doi.org/10.1107/s2414314619009623no claims checked
[4]
moderate
Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice
Shen HW, Jiang XL, Yu AM · 2011 · Drug Metabolism and Disposition
doi.org/10.1124/dmd.111.039107 pubmed 21464174no claims checked
[5]
strong
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE · 2018 · Neuropharmacology
doi.org/10.1016/j.neuropharm.2018.05.012 pubmed 29753748no claims checked
[6]
moderate
Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
Smith DA, Bailey JM, Williams D, Fantegrossi WE · 2014 · The Journal of pharmacology and experimental therapeutics
doi.org/10.1124/jpet.114.219337 pubmed 25271256no claims checked
[7]
moderate
Indolealkylamines: biotransformations and potential drug-drug interactions
Yu AM · 2008 · The AAPS Journal
doi.org/10.1208/s12248-008-9028-5 pubmed 18454322no claims checked
[8]
moderate
DMT analogues: N-ethyl-N-propyl-tryptamine and N-allyl-N-methyltryptamine as their hydro-fumarate salts
Chadeayne AR, Pham DNK, Golen JA, Manke DR · 2020 · Acta Crystallographica Section E: Crystallographic Communications
doi.org/10.1107/s2056989020008683 pubmed 32843999no claims checked
[9]
moderate
The fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocin
Chadeayne AR, Pham DNK, Golen JA, Manke DR · 2019 · Acta Crystallographica Section E Crystallographic Communications
doi.org/10.1107/s2056989019011253 pubmed 31523457no claims checked
[10]
weak
MPT - PsychonautWiki
2024
linkno claims checked
[11]
weak
Methylpropyltryptamine - HandWiki
HandWiki contributors · 2023
linkno claims checked
[12]
moderate
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC · 2008 · Pharmacology, biochemistry, and behavior
pubmed 17905422no claims checked
[13]
moderate
Psychedelics and the human receptorome
Ray TS · 2010 · PLoS ONE
doi.org/10.1371/journal.pone.0009019 pubmed 20126400no claims checked
[14]
moderate
Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE · 2009 · Journal of neural transmission
doi.org/10.1007/s00702-009-0308-8 pubmed 19756361no claims checked
[15]
moderate
The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator
Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE · 2009 · Science
doi.org/10.1126/science.1166127 pubmed 19213917no claims checked
[16]
moderate
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions
Shen HW, Jiang XL, Winter JC, Yu AM · 2010 · Current Drug Metabolism
pubmed 20942780no claims checked
[17]
moderate
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status
Jiang XL, Shen HW, Mager DE, Yu AM · 2013 · Drug Metabolism and Disposition
doi.org/10.1124/dmd.112.050724 pubmed 23393220no claims checked
[18]
moderate
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
McKenna DJ, Repke DB, Lo L, Peroutka SJ · 1990 · Neuropharmacology
pubmed 2139186no claims checked
[19]
moderate
Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
Puigseslloses P, Nadal-Gratacos N, Ketsela G, et al. · 2024 · Molecular Psychiatry
doi.org/10.1038/s41380-024-02506-8 pubmed 38486047no claims checked
[20]
strong
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T · 2018 · Progress in neuro-psychopharmacology & biological psychiatry
doi.org/10.1016/j.pnpbp.2017.09.012 pubmed 28947181no claims checked
[21]
moderate
Recreational use, analysis and toxicity of tryptamines.
Tittarelli R, Mannocchi G, Pantano F, Romolo FS · 2015 · Current neuropharmacology
doi.org/10.2174/1570159x13666141210222409 pubmed 26074742no claims checked
[22]
moderate
Toxicology and Analysis of Psychoactive Tryptamines.
Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA · 2020 · International journal of molecular sciences
doi.org/10.3390/ijms21239279 pubmed 33291798no claims checked
[23]
strong
Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis
Hinkle JT, Graziosi M, Nayak SM, Yaden DB · 2024 · JAMA Psychiatry
doi.org/10.1001/jamapsychiatry.2024.2546 pubmed 39230883no claims checked
[24]
moderate
Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases
Litjens RP, Brunt TM, Alderliefste GJ, Westerink RH · 2014 · European Neuropsychopharmacology
doi.org/10.1016/j.euroneuro.2014.05.008 pubmed 24933532no claims checked
[25]
strong
Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants
Müller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S · 2022 · Psychopharmacology
doi.org/10.1007/s00213-022-06066-z pubmed 35076721no claims checked
[26]
moderate
Serotonin toxicity of serotonergic psychedelics
Malcolm B, Thomas K · 2022 · Psychopharmacology
doi.org/10.1007/s00213-021-05876-x pubmed 34251464no claims checked

Claim Verification

No claim verification has run for this version.

Coverage & Gaps

effect links

166 links · 166 approved · 0 audited0/166 with evidence basis

MPT

Value Provenance

Dosing

oraltrace →

Duration

oral

Safety

Toxicity Profiletrace →

Dependence Profiletrace →

Withdrawal Profiletrace →

Tolerance Profiletrace →

Effects & Profile

Contraindications

Timeline Phases

oral

Dose Tier Summaries

History

Sources

Claim Verification

Coverage & Gaps

oraltrace

Toxicity Profiletrace

Dependence Profiletrace

Withdrawal Profiletrace

Tolerance Profiletrace